DOCSLIB.ORG

Springer Handbook of Enzymes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Springer Handbook of Enzymes Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes EC Number Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2013 This work is subject to copyright. All rights reserved, whether in whole or part of the material concerned, specifically the right of translation, printing and reprinting, reproduction and storage in databases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–10, EC Number Index 1.1.1.1 alcohol dehydrogenase, Vol. 16,p.1 1.1.1.58 tagaturonate reductase, Vol. 17,p.36 1.1.1.2 alcohol dehydrogenase (NADP+), Vol. 16,p.45 1.1.1.59 3-hydroxypropionate dehydrogenase, Vol. 17,p.40 1.1.1.3 homoserine dehydrogenase, Vol. 16,p.84 1.1.1.60 2-hydroxy-3-oxopropionate reductase, Vol. 17, 1.1.1.4 (R,R)-butanediol dehydrogenase, Vol. 16,p.91 p. 42 1.1.1.5 acetoin dehydrogenase, Vol. 16,p.97 1.1.1.61 4-hydroxybutyrate dehydrogenase, Vol. 17,p.46 1.1.1.6 glycerol dehydrogenase, Vol. 16, p. 108 1.1.1.62 estradiol 17b-dehydrogenase, Vol. 17,p.48 1.1.1.7 propanediol-phosphate dehydrogenase, Vol. 16, 1.1.1.63 testosterone 17b-dehydrogenase, Vol. 17,p.63 p. 118 1.1.1.64 testosterone 17b-dehydrogenase (NADP+), Vol. 17, 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+), p. 71 Vol. 16, p. 120 1.1.1.65 pyridoxine 4-dehydrogenase, Vol. 17,p.78 1.1.1.9 d-xylulose reductase, Vol. 16, p. 137 1.1.1.66 w-hydroxydecanoate dehydrogenase, Vol. 17,p.81 1.1.1.10 l-xylulose reductase, Vol. 16, p. 144 1.1.1.67 mannitol 2-dehydrogenase, Vol. 17,p.84 1.1.1.11 d-arabinitol 4-dehydrogenase, Vol. 16, p. 149 1.1.1.68 5,10-methylenetetrahydrofolate reductase, trans- 1.1.1.12 l-arabinitol 4-dehydrogenase, Vol. 16, p. 154 ferred to EC 1.7.99.5, Vol. 17,p.91 1.1.1.13 l-arabinitol 2-dehydrogenase, Vol. 16, p. 156 1.1.1.69 gluconate 5-dehydrogenase, Vol. 17,p.92 1.1.1.14 l-iditol 2-dehydrogenase, Vol. 16, p. 158 1.1.1.70 d-glucronolactone dehydrogenase, deleted, included 1.1.1.15 d-iditol 2-dehydrogenase, Vol. 16, p. 173 in EC 1.2.1.3, Vol. 17,p.97 1.1.1.16 galactitol 2-dehydrogenase, Vol. 16, p. 175 1.1.1.71 alcohol dehydrogenase [NAD(P)+], Vol. 17,p.98 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase, Vol. 16, 1.1.1.72 glycerol dehydrogenase (NADP+), Vol. 17, p. 106 p. 180 1.1.1.73 octanol dehydrogenase, Vol. 17, p. 111 1.1.1.18 inositol 2-dehydrogenase, Vol. 16, p. 188 1.1.1.74 d-aminopropanol dehydrogenase, deleted, reaction 1.1.1.19 l-glucuronate reductase, Vol. 16, p. 193 due to EC 1.1.1.4, Vol. 17, p. 114 1.1.1.20 glucuronolactone reductase, Vol. 16, p. 200 1.1.1.75 (R)-aminopropanol dehydrogenase, Vol. 17, p. 115 1.1.1.21 aldehyde reductase, Vol. 16, p. 203 1.1.1.76 (S,S)-butanediol dehydrogenase, Vol. 17, p. 121 1.1.1.22 UDPglucose 6-dehydrogenase, Vol. 16, p. 221 1.1.1.77 lactaldehyde reductase, Vol. 17, p. 126 1.1.1.23 histidinol dehydrogenase, Vol. 16, p. 229 1.1.1.78 d-lactaldehyde dehydrogenase, Vol. 17, p. 131 1.1.1.24 quinate 5-dehydrogenase, Vol. 16, p. 236 1.1.1.79 glyoxylate reductase (NADP+), Vol. 17, p. 138 1.1.1.25 shikimate 5-dehydrogenase, Vol. 16, p. 241 1.1.1.80 isopropanol dehydrogenase (NADP+), Vol. 17, 1.1.1.26 glyoxylate reductase, Vol. 16, p. 247 p. 144 1.1.1.27 l-lactate dehydrogenase, Vol. 16, p. 253 1.1.1.81 hydroxypyruvate reductase, Vol. 17, p. 147 1.1.1.28 d-lactate dehydrogenase, Vol. 16, p. 274 1.1.1.82 malate dehydrogenase (NADP+), Vol. 17, p. 155 1.1.1.29 glycerate dehydrogenase, Vol. 16, p. 283 1.1.1.83 d-malate dehydrogenase (decarboxylating), 1.1.1.30 3-hydroxybutyrate dehydrogenase, Vol. 16, p. 287 Vol. 17, p. 172 1.1.1.31 3-hydroxyisobutyrate dehydrogenase, Vol. 16, 1.1.1.84 dimethylmalate dehydrogenase, Vol. 17, p. 176 p. 299 1.1.1.85 3-isopropylmalate dehydrogenase, Vol. 17, p. 179 1.1.1.32 mevaldate reductase, Vol. 16, p. 304 1.1.1.86 ketol-acid reductoisomerase, Vol. 17, p. 190 1.1.1.33 mevaldate reductase (NADPH), Vol. 16, p. 307 1.1.1.87 3-carboxy-2-hydroxyadipate dehydrogenase, 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH2), Vol. 17, p. 198 Vol. 16, p. 309 1.1.1.88 hydroxymethylglutaryl-CoA reductase, Vol. 17, 1.1.1.35 3-hydroxyacyl-CoA dehydrogenase, Vol. 16, p. 318 p. 200 1.1.1.36 acetoacetyl-CoA reductase, Vol. 16, p. 328 1.1.1.89 dihydroxyisovalerate dehydrogenase (isomerizing), 1.1.1.37 malate dehydrogenase, Vol. 16, p. 336 deleted, included in EC 1.1.1.86, Vol. 17, p. 208 1.1.1.38 malate dehydrogenase (oxaloacetate-decarboxylat- 1.1.1.90 aryl-alcohol dehydrogenase, Vol. 17, p. 209 ing), Vol. 16, p. 360 1.1.1.91 aryl-alcohol dehydrogenase (NADP+), Vol. 17, 1.1.1.39 malate dehydrogenase (decarboxylating), Vol. 16, p. 218 p. 371 1.1.1.92 oxaloglycolate reductase (decarboxylating), 1.1.1.40 malate dehydrogenase (oxaloacetate-decarboxylat- Vol. 17, p. 225 ing, NADP+), Vol. 16, p. 381 1.1.1.93 tartrate dehydrogenase, Vol. 17, p. 228 1.1.1.41 isocitrate dehydrogenase (NAD+), Vol. 16, p. 394 1.1.1.94 glycerol-3-phosphate dehydrogenase [NAD(P)+], 1.1.1.42 isocitrate dehydrogenase (NADP+), Vol. 16, p. 402 Vol. 17, p. 235 1.1.1.43 phosphogluconate 2-dehydrogenase, Vol. 16, 1.1.1.95 phosphoglycerate dehydrogenase, Vol. 17, p. 238 p. 414 1.1.1.96 diiodophenylpyruvate reductase, Vol. 17, p. 248 1.1.1.44 phosphogluconate dehydrogenase (decarboxylat- 1.1.1.97 3-hydroxybenzyl-alcohol dehydrogenase, Vol. 17, ing), Vol. 16, p. 421 p. 252 1.1.1.45 l-gulonate 3-dehydrogenase, Vol. 16, p. 443 1.1.1.98 (R)-2-hydroxy-fatty-acid dehydrogenase, Vol. 17, 1.1.1.46 l-arabinose 1-dehydrogenase, Vol. 16, p. 448 p. 255 1.1.1.47 glucose 1-dehydrogenase, Vol. 16, p. 451 1.1.1.99 (S)-2-hydroxy-fatty-acid dehydrogenase, Vol. 17, 1.1.1.48 galactose 1-dehydrogenase, Vol. 16, p. 467 p. 257 1.1.1.49 glucose-6-phosphate 1-dehydrogenase, Vol. 16, 1.1.1.100 3-oxoacyl-[acyl-carrier-protein] reductase, p. 474 Vol. 17, p. 259 1.1.1.50 3a-hydroxysteroid dehydrogenase (B-specific), 1.1.1.101 acylglycerone-phosphate reductase, Vol. 17, p. 266 Vol. 16, p. 487 1.1.1.102 3-dehydrosphinganine reductase, Vol. 17, p. 273 1.1.1.51 3(or 17)b-hydroxysteroid dehydrogenase, Vol. 17, 1.1.1.103 l-threonine 3-dehydrogenase, Vol. 17, p. 276 p. 1 1.1.1.104 4-oxoproline reductase, Vol. 17, p. 285 1.1.1.52 3a-hydroxycholanate dehydrogenase, Vol. 17,p.7 1.1.1.105 retinol dehydrogenase, Vol. 17, p. 287 1.1.1.53 3a (or 20b)-hydroxysteroid dehydrogenase, 1.1.1.106 pantoate 4-dehydrogenase, Vol. 17, p. 291 Vol. 17,p.9 1.1.1.107 pyridoxal 4-dehydrogenase, Vol. 17, p. 294 1.1.1.54 allyl-alcohol dehydrogenase, Vol. 17,p.20 1.1.1.108 carnitine 3-dehydrogenase, Vol. 17, p. 296 1.1.1.55 lactaldehyde reductase (NADPH), Vol. 17,p.24 1.1.1.109 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, 1.1.1.56 ribitol 2-dehydrogenase, Vol. 17,p.26 transferred to EC 1.3.1.28, Vol. 17, p. 303 1.1.1.57 fructuronate reductase, Vol. 17,p.32 1.1.1.110 indolelactate dehydrogenase, Vol. 17, p. 304 Springer Handbook of Enzymes # Springer Verlag Berlin Heidelberg 2001–2013 1 Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–10, EC Number Index 1.1.1.111 3-(imidazol-5-yl)lactate dehydrogenase, Vol. 17, 1.1.1.159 7a-hydroxysteroid dehydrogenase, Vol. 18,p.21 p. 306 1.1.1.160 dihydrobunolol dehydrogenase, Vol. 18,p.30 1.1.1.112 indanol dehydrogenase, Vol. 17, p. 308 1.1.1.161 cholestanetetraol 26-dehydrogenase, Vol. 18,p.32 1.1.1.113 l-xylose 1-dehydrogenase, Vol. 17, p. 316 1.1.1.162 erythrulose reductase, Vol. 18,p.35 1.1.1.114 apiose 1-reductase, Vol. 17, p. 318 1.1.1.163 cyclopentanol dehydrogenase, Vol. 18,p.41 1.1.1.115 ribose 1-dehydrogenase (NADP+), Vol. 17, p. 321 1.1.1.164 hexadecanol dehydrogenase, Vol. 18,p.43 1.1.1.116 d-arabinose 1-dehydrogenase, Vol. 17, p. 323 1.1.1.165 2-alkyn-1-ol dehydrogenase, Vol. 18,p.46 1.1.1.117 d-arabinose 1-dehydrogenase [NAD(P)+], Vol. 17, 1.1.1.166 hydroxycyclohexanecarboxylate dehydrogenase, p. 328 Vol. 18,p.49 1.1.1.118 glucose 1-dehydrogenase (NAD+), Vol. 17, p. 332 1.1.1.167 hydroxymalonate dehydrogenase, Vol. 18,p.52 1.1.1.119 glucose 1-dehydrogenase (NADP+), Vol. 17, p. 335 1.1.1.168 2-dehydropantoyl-lactone reductase (A-specific), 1.1.1.120 galactose 1-dehydrogenase (NADP+), Vol.
Load more

Recommended publications
  • Downloaded 10/5/2021 9:43:05 AM
    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Aromatic side-chain flips orchestrate the conformational sampling of functional loops in Cite this: Chem. Sci.,2021,12,9318 † All publication charges for this article human histone deacetylase 8 have been paid for by the Royal Society a a bcd of Chemistry Vaibhav Kumar Shukla, ‡ Lucas Siemons, ‡ Francesco L. Gervasio and D. Flemming Hansen *a Human histone deacetylase 8 (HDAC8) is a key hydrolase in gene regulation and an important drug-target. High-resolution structures of HDAC8 in complex with substrates or inhibitors are available, which have provided insights into the bound state of HDAC8 and its function. Here, using long all-atom unbiased molecular dynamics simulations and Markov state modelling, we show a strong correlation between the conformation of aromatic side chains near the active site and opening and closing of the surrounding functional loops of HDAC8. We also investigated two mutants known to allosterically downregulate the enzymatic activity of HDAC8. Based on experimental data, we hypothesise that I19S-HDAC8 is unable to Received 6th April 2021 Creative Commons Attribution 3.0 Unported Licence. release the product, whereas both product release and substrate binding are impaired in the S39E- Accepted 27th May 2021 HDAC8 mutant. The presented results deliver detailed insights into the functional dynamics of HDAC8 DOI: 10.1039/d1sc01929e and provide a mechanism for the substantial downregulation caused by allosteric mutations, including rsc.li/chemical-science a disease causing one. Introduction II (HDAC-4, -5, -6, -7, -9, and HDAC10), and class III (SIRT1-7) have sequence similarity to yeast Rpd3, Hda1, and Sir2, Acetylation of lysine side chains occurs as a co-translation or respectively, whereas class IV (HDAC11) shares sequence simi- 2 This article is licensed under a post-translational modication of proteins and was rst iden- larity with both class I and II proteins.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Gentaur Products List
    Chapter 2 : Gentaur Products List • Rabbit Anti LAMR1 Polyclonal Antibody Cy5 Conjugated Conjugated • Rabbit Anti Podoplanin gp36 Polyclonal Antibody Cy5 • Rabbit Anti LAMR1 CT Polyclonal Antibody Cy5 • Rabbit Anti phospho NFKB p65 Ser536 Polyclonal Conjugated Conjugated Antibody Cy5 Conjugated • Rabbit Anti CHRNA7 Polyclonal Antibody Cy5 Conjugated • Rat Anti IAA Monoclonal Antibody Cy5 Conjugated • Rabbit Anti EV71 VP1 CT Polyclonal Antibody Cy5 • Rabbit Anti Connexin 40 Polyclonal Antibody Cy5 • Rabbit Anti IAA Indole 3 Acetic Acid Polyclonal Antibody Conjugated Conjugated Cy5 Conjugated • Rabbit Anti LHR CGR Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Integrin beta 7 Polyclonal Antibody Cy5 • Rabbit Anti Natrexone Polyclonal Antibody Cy5 Conjugated • Rabbit Anti MMP 20 Polyclonal Antibody Cy5 Conjugated Conjugated • Rabbit Anti Melamine Polyclonal Antibody Cy5 Conjugated • Rabbit Anti BCHE NT Polyclonal Antibody Cy5 Conjugated • Rabbit Anti NAP1 NAP1L1 Polyclonal Antibody Cy5 • Rabbit Anti Acetyl p53 K382 Polyclonal Antibody Cy5 • Rabbit Anti BCHE CT Polyclonal Antibody Cy5 Conjugated Conjugated Conjugated • Rabbit Anti HPV16 E6 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti CCP Polyclonal Antibody Cy5 Conjugated • Rabbit Anti JAK2 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti HPV18 E6 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti HDC Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Microsporidia protien Polyclonal Antibody Cy5 • Rabbit Anti HPV16 E7 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Neurocan Polyclonal
    [Show full text]
  • The Role of Protein Crystallography in Defining the Mechanisms of Biogenesis and Catalysis in Copper Amine Oxidase
    Int. J. Mol. Sci. 2012, 13, 5375-5405; doi:10.3390/ijms13055375 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review The Role of Protein Crystallography in Defining the Mechanisms of Biogenesis and Catalysis in Copper Amine Oxidase Valerie J. Klema and Carrie M. Wilmot * Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 321 Church St. SE, Minneapolis, MN 55455, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-612-624-2406; Fax: +1-612-624-5121. Received: 6 April 2012; in revised form: 22 April 2012 / Accepted: 26 April 2012 / Published: 3 May 2012 Abstract: Copper amine oxidases (CAOs) are a ubiquitous group of enzymes that catalyze the conversion of primary amines to aldehydes coupled to the reduction of O2 to H2O2. These enzymes utilize a wide range of substrates from methylamine to polypeptides. Changes in CAO activity are correlated with a variety of human diseases, including diabetes mellitus, Alzheimer’s disease, and inflammatory disorders. CAOs contain a cofactor, 2,4,5-trihydroxyphenylalanine quinone (TPQ), that is required for catalytic activity and synthesized through the post-translational modification of a tyrosine residue within the CAO polypeptide. TPQ generation is a self-processing event only requiring the addition of oxygen and Cu(II) to the apoCAO. Thus, the CAO active site supports two very different reactions: TPQ synthesis, and the two electron oxidation of primary amines. Crystal structures are available from bacterial through to human sources, and have given insight into substrate preference, stereospecificity, and structural changes during biogenesis and catalysis.
    [Show full text]
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Purine Metabolism in Cultured Endothelial Cells
    PURINE METABOLISM IN MAN-III Biochemical, Immunological, and Cancer Research Edited by Aurelio Rapado Fundacion Jimenez Diaz Madrid, Spain R.W.E. Watts M.R.C. Clinical Research Centre Harrow, England and Chris H.M.M. De Bruyn Department of Human Genetics University of Nijmegen Faculty of Medicine Nijmegen, The Netherlands PLENUM PRESS · NEW YORK AND LONDON Contents of Part Β I. PURINE METABOLISM PATHWAYS AND REGULATION A. De Novo Synthesis; Precursors and Regulation De Novo Purine Synthesis in Cultured Human Fibroblasts 1 R.B. Gordon, L. Thompson, L.A. Johnson, and B.T. Emmerson Comparative Metabolism of a New Antileishmanial Agent, Allopurinol Riboside, in the Parasite and the Host Cell 7 D. J. Nelson, S.W. LaFon, G.B. Elion, J.J. Marr, and R.L. Berens Purine Metabolism in Rat Skeletal Muscle 13 E. R. Tully and T.G. Sheehan Alterations in Purine Metabolism in Cultured Fibroblasts with HGPRT Deficiency and with PRPPP Synthetase Superactivity 19 E. Zoref-Shani and 0. Sperling Purine Metabolism in Cultured Endothelial Cells 25 S. Nees, A.L. Gerbes, B. Willershausen-Zönnchen, and E. Gerlach Determinants of 5-Phosphoribosyl-l-Pyrophosphate (PRPP) Synthesis in Human Fibroblasts 31 K.0, Raivio, Ch. Lazar, H. Krumholz, and M.A. Becker Xanthine Oxidoreductase Inhibition by NADH as a Regulatory Factor of Purine Metabolism 35 M.M. Jezewska and Z.W. Kaminski vii viii CONTENTS OF PART Β Β. Nucleotide Metabolism Human Placental Adenosine Kinase: Purification and Characterization 41 CM. Andres, T.D. Palella, and I.H. Fox Long-Term Effects of Ribose on Adenine Nucleotide Metabolism in Isoproterenol-Stimulated Hearts .
    [Show full text]
  • Metabolism of Purines and Pyrimidines in Health and Disease
    39th Meeting of the Polish Biochemical Society Gdañsk 16–20 September 2003 SESSION 6 Metabolism of purines and pyrimidines in health and disease Organized by A. C. Sk³adanowski, A. Guranowski 182 Session 6. Metabolism of purines and pyrimidines in health and disease 2003 323 Lecture The role of DNA methylation in cytotoxicity mechanism of adenosine analogues in treatment of leukemia Krystyna Fabianowska-Majewska Zak³ad Chemii Medycznej IFiB, Uniwersytet Medyczny, ul. Mazowiecka 6/8, 92 215 £ódŸ Changes in DNA methylation have been recognized tory effects of cladribine and fludarabine on DNA as one of the most common molecular alterations in hu- methylation, after 48 hr growth of K562 cells with the man neoplastic diseases and hypermethylation of drugs, are non-random and affect mainly CpG rich is- gene-promoter regions is one of the most frequent lands or CCGG sequences but do not affect sepa- mechanisms of the loss of gene functions. For this rea- rately-located CpG sequences. The analysis showed son, DNA methylation may be a tool for detection of that cladribine (0.1 mM) reduced the methylated early cell transformations as well as predisposition to cytosines in CpG islands and CCGG sequences to a sim- metastasis process. Moreover, DNA methylation seems ilar degree. The inhibition of cytosine methylation by to be a promissing target for new preventive and thera- fludarabine (3 mM) was observed mainly in CCGG se- peutic strategies. quences, sensitive to HpaII, but the decline in the meth- Our studies on DNA methylation and cytotoxicity ylated cytosine, located in CpG island was 2-fold lower mechanism of antileukemic drugs, cladribine and than that with cladribine.
    [Show full text]
  • C1 Assimilation in Obligate Methylotrophs and Restricted Facultative Methylotrophs by JOHN COLBY* and LEONARD J
    Biochem. J. (1975) 148, 513-520 513 Printed in Great Britain Enzymological Aspects ofthe Pathways for Trimethylamine Oxidation and C1 Assimilation in Obligate Methylotrophs and Restricted Facultative Methylotrophs By JOHN COLBY* and LEONARD J. ZATMAN Department ofMicrobiology, University ofReading, Reading RG1 5AQ, U.K. (Received8 January 1975) 1. Extracts of trimethylamine-grown W6A and W3A1 (type M restricted facultative methylotrophs) contain trimethylamine dehydrogenase whereas similar extracts of Bacillus PM6 and Bacillus S2A1 (type L restricted facultative methylotrophs) contain trimethylamine mono-oxygenase and trimethylamine N-oxide demethylase but no trimethylamine dehydrogenase. 2. Extracts oftherestricted facultatives and ofthe obligate methylotroph C2A1 contain hexulose phosphate synthase-hexulose phosphate isomerase activity; hydroxypyruvate reductase was not detected. 3. Neither the restricted facultatives nor the obligates 4B6 and C2A1 contain all the enzymes ofthe hexulose phos- phatecycleofformaldehyde assimilation as originallyproposed byKemp & Quayle (1967). 4. Organisms PM6 and S2A1 lack transaldolase and use a modified cycle involving sedoheptulose 1,7-diphosphate and sedoheptulose diphosphatase. 5. The obligates 4B6 and C2A1, and the type M organisms W6A and W3A1, use a different modification of the assimilatory hexulose phosphate cycle involving the Entner-Doudoroff-pathway enzymes phosphogluconate dehydratase and phospho-2-keto-3-deoxygluconate aldolase. Thelackoffructosediphosphatealdolaseandhexosediphosphataseintheseorganismsmay
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Supplementary Table 1. All Differentially Expressed Genes from Microarray Screening Analysis
    Supplementary Table 1. All differentially expressed genes from microarray screening analysis. FCa (Gal-KD Gene Symbol Gene Name p-Value versus Vector) Up-regulated genes HAPLN1 hyaluronan and proteoglycan link protein 1 10.49 0.0027085 THBS1 thrombospondin 1 9.20 0.0022192 ODC1 ornithine decarboxylase 1 6.38 0.0055776 TGM2 transglutaminase 2 4.76 0.0015627 IL7R interleukin 7 receptor 4.75 0.0017245 SERINC2 serine incorporator 2 4.51 0.0014919 ITM2C integral membrane protein 2C 4.32 0.0044644 SERPINB7 serpin peptidase inhibitor, clade B, member 7 4.18 0.0081136 tumor necrosis factor receptor superfamily, member TNFRSF10D 4.01 0.0085561 10d TAGLN transgelin 3.90 0.0099963 LRRN4 leucine rich repeat neuronal 4 3.82 0.0046513 TGFB2 transforming growth factor beta 2 3.51 0.0035017 CPA4 carboxypeptidase A4 3.43 0.0008452 EPB41L3 erythrocyte membrane protein band 4.1-like 3 3.34 0.0025309 NRG1 neuregulin 1 3.28 0.0079724 F3 coagulation factor III (thromboplastin, tissue factor) 3.27 0.0038968 POLR3G polymerase III polypeptide G 3.26 0.0070675 SEMA7A semaphorin 7A 3.20 0.0087335 NT5E 5-nucleotidase 3.17 0.0036353 CAMK2N1 calmodulin-dependent protein kinase II inhibitor 1 3.07 0.0090141 TIMP3 TIMP metallopeptidase inhibitor 3 3.03 0.0047953 SERPINE1 serpin peptidase inhibitor, clade E 2.97 0.0053652 MALL mal, T-cell differentiation protein-like 2.88 0.0078205 DDAH1 dimethylarginine dimethylaminohydrolase 1 2.86 0.0002895 WDR3 WD repeat domain 3 2.85 0.0058842 WNT5A Wnt Family Member 5A 2.81 0.0043796 GPR1 G protein-coupled receptor 1 2.81 0.0021313
    [Show full text]
  • Phylogenetic Analysis, Subcellular Localization, and Expression
    BMC Plant Biology BioMed Central Research article Open Access Phylogenetic analysis, subcellular localization, and expression patterns of RPD3/HDA1 family histone deacetylases in plants Malona V Alinsug, Chun-Wei Yu and Keqiang Wu* Address: Institute of Plant Biology, College of Life Science, National Taiwan University, Taipei, Taiwan Email: Malona V Alinsug - [email protected]; Chun-Wei Yu - [email protected]; Keqiang Wu* - [email protected] * Corresponding author Published: 28 March 2009 Received: 26 November 2008 Accepted: 28 March 2009 BMC Plant Biology 2009, 9:37 doi:10.1186/1471-2229-9-37 This article is available from: http://www.biomedcentral.com/1471-2229/9/37 © 2009 Alinsug et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Although histone deacetylases from model organisms have been previously identified, there is no clear basis for the classification of histone deacetylases under the RPD3/ HDA1 superfamily, particularly on plants. Thus, this study aims to reconstruct a phylogenetic tree to determine evolutionary relationships between RPD3/HDA1 histone deacetylases from six different plants representing dicots with Arabidopsis thaliana, Populus trichocarpa, and Pinus taeda, monocots with Oryza sativa and Zea mays, and the lower plants with Physcomitrella patens. Results: Sixty two histone deacetylases of RPD3/HDA1 family from the six plant species were phylogenetically analyzed to determine corresponding orthologues. Three clusters were formed separating Class I, Class II, and Class IV.
    [Show full text]
  • Investigation of Plasma Metabolomics and Neurotransmitter Dysfunction In
    RSC Advances View Article Online PAPER View Journal | View Issue Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Cite this: RSC Adv.,2019,9,18308 Alzheimer's disease rat induced by amyloid beta 25- 35 Mengying Wei,ab Yuanyuan Liu,a Zifeng Pi, b Kexin Yue,a Shizhe Li,c Mingxin Hu,a Zhiqiang Liu,b Fengrui Song b and Zhongying Liu*a Alzheimer's disease (AD) has become one of the major diseases endangering the health of the elderly. Clarifying the features of each AD animal model is valuable for understanding the onset and progression of diseases and developing potential treatments in the pharmaceutical industry. In this study, we aimed to clarify plasma metabolomics and neurotransmitter dysfunction in the process of AD model rat induced by amyloid beta 25-35 (Ab 25-35). Firstly, Morris Water Maze (MWM) test was used to investigate cognitive impairment in AD rat after 2, 4 and 8 weeks of modelling. Based on this, the effects on levels Creative Commons Attribution-NonCommercial 3.0 Unported Licence. of AD-related enzymes and eight neurotransmitters were analyzed. And plasma metabolomics analysis based on ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) was used to research the metabolic disturbances in the process of AD rat. The results shown the injury on the spatial learning ability of AD rats was gradually aggravated within 4 weeks, reached the maximum at 4 weeks and then was stable until 8 weeks. During 8 weeks of modeling, the levels of enzymes including b-secretase, g-secretase, glycogen synthase kinase-3b (GSK- 3b), acetyl cholinesterase (AchE) and nitric oxide synthase (NOS) were significant increased in the plasma of AD rats.
    [Show full text]